Intra-ImmuSG seeks to develop a safer and more effective cancer therapy via a combination of a targeted therapy and immunotherapy.

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a ...

Study of 2.4 million participants reveals potential advantages for cardiometabolic and psychiatric conditions alongside increased risks of gastrointestinal and musculoskeletal issues Study ...

A recent case report by Sahota and colleagues has provided new insights into treatment of dysglycemia via dopamine (DA) receptor stimulation in the setting of autoimmune diabetes (1). Briefly, a ...

No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs. those using a DPP-IV inhibitor. Women may have a lower risk for thyroid cancer ...